These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26314396)

  • 1. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
    Grom AA; Ilowite NT; Pascual V; Brunner HI; Martini A; Lovell D; Ruperto N; ; Leon K; Lheritier K; Abrams K
    Arthritis Rheumatol; 2016 Jan; 68(1):218-28. PubMed ID: 26314396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
    Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab.
    Yokota S; Itoh Y; Morio T; Sumitomo N; Daimaru K; Minota S
    J Rheumatol; 2015 Apr; 42(4):712-22. PubMed ID: 25684767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat N; Horneff G; Brik R; McCann L; Kasapcopur O; Rutkowska-Sak L; Schneider R; Berkun Y; Calvo I; Erguven M; Goffin L; Hofer M; Kallinich T; Oliveira SK; Uziel Y; Viola S; Nistala K; Wouters C; Cimaz R; Ferrandiz MA; Flato B; Gamir ML; Kone-Paut I; Grom A; Magnusson B; Ozen S; Sztajnbok F; Lheritier K; Abrams K; Kim D; Martini A; Lovell DJ; ;
    N Engl J Med; 2012 Dec; 367(25):2396-406. PubMed ID: 23252526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
    Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat NM; Horneff G; Kasapcopur O; Schneider R; Anton J; Barash J; Berner R; Corona F; Cuttica R; Fouillet-Desjonqueres M; Fischbach M; Foster HE; Foell D; Radominski SC; Ramanan AV; Trauzeddel R; Unsal E; Levy J; Vritzali E; Martini A; Lovell DJ;
    Ann Rheum Dis; 2018 Dec; 77(12):1710-1719. PubMed ID: 30269054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Shimizu M; Mizuta M; Okamoto N; Yasumi T; Iwata N; Umebayashi H; Okura Y; Kinjo N; Kubota T; Nakagishi Y; Nishimura K; Mohri M; Yashiro M; Yasumura J; Wakiguchi H; Mori M
    Pediatr Rheumatol Online J; 2020 Jan; 18(1):2. PubMed ID: 31924225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
    Barut K; Adrovic A; Sahin S; Tarcin G; Tahaoglu G; Koker O; Yildiz M; Kasapcopur O
    Int J Rheum Dis; 2019 Sep; 22(9):1661-1669. PubMed ID: 31273940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy.
    Ulu K; Aliyev E; Kılıç Könte E; Tanatar A; Türkmen Ş; Doğantan Ş; Kızıldağ Z; Kasap Demir B; Gezgin Yıldırım D; Otar Yener G; Öztürk K; Baba Ö; Açarı C; Kılbaş G; Taşkın SN; Haşlak F; Çağlayan Ş; Bağlan E; Dundar HA; Başaran Ö; Barut K; Karadağ ŞG; Coşkuner T; Sönmez HE; Yüksel S; Kalyoncu M; Bakkaloğlu SA; Ünsal E; Paç Kısaarslan A; Bilginer Y; Aktay Ayaz N; Kasapçopur Ö; Özen S; Sözeri B
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI167-SI172. PubMed ID: 38441301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
    Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
    Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
    Ruperto N; Quartier P; Wulffraat N; Woo P; Ravelli A; Mouy R; Bader-Meunier B; Vastert SJ; Noseda E; D'Ambrosio D; Lecot J; Chakraborty A; Martini A; Chioato A;
    Arthritis Rheum; 2012 Feb; 64(2):557-67. PubMed ID: 21953497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
    Orrock JE; Ilowite NT
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
    Davì S; Minoia F; Pistorio A; Horne A; Consolaro A; Rosina S; Bovis F; Cimaz R; Gamir ML; Ilowite NT; Kone-Paut I; Feitosa de Oliveira SK; McCurdy D; Silva CA; Sztajnbok F; Tsitsami E; Unsal E; Weiss JE; Wulffraat N; Abinun M; Aggarwal A; Apaz MT; Astigarraga I; Corona F; Cuttica R; D'Angelo G; Eisenstein EM; Hashad S; Lepore L; Mulaosmanovic V; Nielsen S; Prahalad S; Rigante D; Stanevicha V; Sterba G; Susic G; Takei S; Trauzeddel R; Zletni M; Ruperto N; Martini A; Cron RQ; Ravelli A;
    Arthritis Rheumatol; 2014 Oct; 66(10):2871-80. PubMed ID: 25044674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
    Brunner HI; Quartier P; Alexeeva E; Constantin T; Koné-Paut I; Marzan K; Schneider R; Wulffraat NM; Chasnyk V; Tirosh I; Kallinich T; Kuemmerle-Deschner J; Wouters C; Lauwerys B; Nikishina I; Trachana M; Vougiouka O; Martini A; Lovell DJ; Levy J; Vritzali E; Ruperto N;
    Arthritis Rheumatol; 2020 Dec; 72(12):2147-2158. PubMed ID: 32648697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort.
    De Matteis A; Bracaglia C; Pires Marafon D; Piscitelli AL; Alessio M; Naddei R; Orlando F; Filocamo G; Minoia F; Ravelli A; Tibaldi J; Cimaz R; Marino A; Simonini G; Mastrolia MV; La Torre F; Tricarico I; Licciardi F; Montin D; Maggio MC; Alizzi C; Martini G; Civino A; Gallizzi R; Olivieri AN; Ardenti Morini F; Conti G; De Benedetti F; Pardeo M
    Rheumatology (Oxford); 2022 Apr; 61(4):1621-1629. PubMed ID: 34343275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
    Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
    Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience.
    Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y
    Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of different drugs in patients with systemic juvenile idiopathic arthritis: A systematic review and network meta-analysis.
    Wang B; Zhang Y; Zhao Z; Ping J; Zhou L; Wang Y; Zhang Y
    Medicine (Baltimore); 2024 May; 103(18):e38002. PubMed ID: 38701278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis.
    Reddy VV; Myles A; Cheekatla SS; Singh S; Aggarwal A
    Int J Rheum Dis; 2014 Mar; 17(3):261-7. PubMed ID: 24417800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
    Ravelli A; Minoia F; Davì S; Horne A; Bovis F; Pistorio A; Aricò M; Avcin T; Behrens EM; De Benedetti F; Filipovic L; Grom AA; Henter JI; Ilowite NT; Jordan MB; Khubchandani R; Kitoh T; Lehmberg K; Lovell DJ; Miettunen P; Nichols KE; Ozen S; Pachlopnik Schmid J; Ramanan AV; Russo R; Schneider R; Sterba G; Uziel Y; Wallace C; Wouters C; Wulffraat N; Demirkaya E; Brunner HI; Martini A; Ruperto N; Cron RQ; ; ; ;
    Arthritis Rheumatol; 2016 Mar; 68(3):566-76. PubMed ID: 26314788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Macrophage activation syndrome in Chinese children with systemic onset juvenile idiopathic arthritis].
    Li CF; He XH; Kuang WY; Han TX; Zhou YF
    Zhonghua Er Ke Za Zhi; 2006 Nov; 44(11):806-11. PubMed ID: 17274865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.